These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 21864451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 5. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA.
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 9. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E, Gastpar M.
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [Abstract] [Full Text] [Related]

  • 10. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, Coghill DR, Kryzhanovskaya LA, Savill NC.
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [Abstract] [Full Text] [Related]

  • 11. Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine.
    Yamaguchi H, Nagumo K, Nakashima T, Kinugawa Y, Kumaki S.
    Eur J Pediatr; 2014 Dec; 173(12):1631-4. PubMed ID: 24233333
    [Abstract] [Full Text] [Related]

  • 12. Increased blood pressure and atomoxetine.
    Dworkin N.
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510. PubMed ID: 15908831
    [No Abstract] [Full Text] [Related]

  • 13. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
    Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ, Atomoxetine Low-dose Study Group.
    Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.
    Donner R, Michaels MA, Ambrosini PJ.
    Biol Psychiatry; 2007 Mar 01; 61(5):706-12. PubMed ID: 16899230
    [Abstract] [Full Text] [Related]

  • 16. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
    Fernández-Jaén A, Fernández-Mayoralas DM, Calleja Pérez B, Muñoz Jareño N, Campos Díaz Mdel R.
    Pediatr Neurol; 2010 Nov 01; 43(5):341-7. PubMed ID: 20933178
    [Abstract] [Full Text] [Related]

  • 17. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
    Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J.
    J Am Acad Child Adolesc Psychiatry; 2007 Feb 01; 46(2):242-51. PubMed ID: 17242628
    [Abstract] [Full Text] [Related]

  • 18. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy.
    Torres A, Whitney J, Rao S, Tilley C, Lobel R, Gonzalez-Heydrich J.
    Epilepsy Behav; 2011 Jan 01; 20(1):95-102. PubMed ID: 21146461
    [Abstract] [Full Text] [Related]

  • 19. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
    Wernicke JF, Kratochvil CJ.
    J Clin Psychiatry; 2002 Jan 01; 63 Suppl 12():50-5. PubMed ID: 12562062
    [Abstract] [Full Text] [Related]

  • 20. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.
    Zeiner P, Gjevik E, Weidle B.
    Acta Paediatr; 2011 Sep 01; 100(9):1258-61. PubMed ID: 21392103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.